1
Clinical Trials associated with CD19/BCMA-targeted CAR-T lentiviral vector drug(Shenzhen Genocury Biotech) / RecruitingNot ApplicableIIT A Clinical Study of the Safety, Tolerability and Preliminary Efficacy of CD19/BCMA-targeted CAR-T Therapy in Refractory Autoimmune Diseases
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with refractory autoimmune diseases. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of CD19/BCMA CAR-T in the treatment of refractory autoimmune diseases.
Start Date22 Mar 2026 |
Sponsor / Collaborator- |
100 Clinical Results associated with CD19/BCMA-targeted CAR-T lentiviral vector drug(Shenzhen Genocury Biotech)
100 Translational Medicine associated with CD19/BCMA-targeted CAR-T lentiviral vector drug(Shenzhen Genocury Biotech)
100 Patents (Medical) associated with CD19/BCMA-targeted CAR-T lentiviral vector drug(Shenzhen Genocury Biotech)
100 Deals associated with CD19/BCMA-targeted CAR-T lentiviral vector drug(Shenzhen Genocury Biotech)